TP53 and nonpapillary renal cell carcinoma: Consistent with previous reports4,7,15,16,25, our study confirmed frequent alterations in key ccRCC drivers, including VHL (71%), PBRM1 (38%), BAP1 (17%), SETD2 (14%), KDM5C (8%), and TP53 (6%) mutations (Fig. 1a, Supplementary Fig. 1a, and Supplementary Data 7).